Literature DB >> 27980025

Individualized Tamoxifen Dose Escalation-Response.

Daniel L Hertz1, James M Rae2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27980025      PMCID： PMC8330639          DOI： 10.1158/1078-0432.CCR-16-2351

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  3 in total

1.  Seven alternatives to evidence-based medicine.

Authors:  D Isaacs; D Fitzgerald
Journal:  Oncologist       Date:  2001

2.  Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility.

Authors:  Daniel L Hertz; James M Rae
Journal:  Clin Cancer Res       Date:  2016-03-24       Impact factor: 12.531

3.  Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.

Authors:  Daniel L Hertz; Allison Deal; Joseph G Ibrahim; Christine M Walko; Karen E Weck; Steven Anderson; Gustav Magrinat; Oludamilola Olajide; Susan Moore; Rachel Raab; Daniel R Carrizosa; Steven Corso; Garry Schwartz; Mark Graham; Jeffrey M Peppercorn; David R Jones; Zeruesenay Desta; David A Flockhart; James P Evans; Howard L McLeod; Lisa A Carey; William J Irvin
Journal:  Oncologist       Date:  2016-05-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.